Surrozen Q1 net loss widens to $14.3M; cash at $61.7M; SZN-043 and SZN-1326 trials enroll

Surrozen, Inc./DE

2023-Q1 EPS reported -$0.48

Net loss of $14.3M vs $7.9M in Q1 2022, driven by $1.2M restructuring charges and higher G&A.
Cash, equivalents and marketable securities $61.7M, down from $75.8M at Dec 31, 2022.
R&D expenses $8.1M, down from $9.4M YoY due to January 2023 restructuring reducing workforce ~25%.
SZN-043 Phase 1a enrollment ongoing in chronic liver disease; safety data expected end of 2023.
SZN-1326 Phase 1a re-initiated in Q2 2023; safety data also expected by end of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surrozen, Inc./DE reported first quarter ended March 31, 2023 results: net income $14.3 million.

Period: first quarter ended March 31, 2023
Net income: $14.3 million
Result: reported results

Exact text from the filing

Surrozen, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Surrozen, Inc./DE filing history →

Source: SEC EDGAR

accession 0000950170-23-020519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.